TherapeuticsMD Inc. buy marge
Start price
19.08.19
/
50%
€129.23
Target price
04.11.21
€350.00
Performance (%)
-74.85%
End price
05.11.21
€32.50
Summary
This prediction ended on 05.11.21 with a price of €32.50. The BUY prediction by marge for TherapeuticsMD Inc. performed very badly with a performance of -74.85%. marge has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
TherapeuticsMD Inc. | -0.971% | -0.971% | -36.250% | -96.483% |
iShares Core DAX® | 2.149% | 5.415% | 21.385% | 22.595% |
iShares Nasdaq 100 | 0.838% | 1.926% | 44.386% | 55.330% |
iShares Nikkei 225® | 1.143% | 2.887% | 27.641% | 9.481% |
iShares S&P 500 | 1.265% | 3.698% | 33.327% | 49.646% |
Comments by marge for this prediction
In the thread Therapeuticsmd Inc. diskutieren
Buy mit Kursziel 7,0
This small cap healthcare concerns seeing significant and recent insider buying here during the dog days of summer. Six insiders picked up just under $400K in new shares in aggregate between August 9th and August 15th. This follows two director buys in May totaling just over $100,000. Those were the first insider buys since August of 2018 and came after months of frequent and substantial insider selling by numerous insiders.
Canacord Genuity reiterated their Buy rating and $13 price target on TXMD last week. Immediately after second quarter results, Northland Securities maintained their Buy rating and identical $13 price target on Therapeutics MD.
Canacord Genuity reiterated their Buy rating and $13 price target on TXMD last week. Immediately after second quarter results, Northland Securities maintained their Buy rating and identical $13 price target on Therapeutics MD.
In the thread Trading Therapeuticsmd Inc.
Die von marge gewählte maximale Laufzeit wurde überschritten